# Tennessee Oncology

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/tennessee-oncology/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 91.5 |
| Citations | 371,118 |
| City | Nashville |
| Country | US |
| Description | Tennessee Oncology is a research organisation in Nashville, US. OpenAlex records 3,841 works and 371,118 citations for it. 539 researchers list it as their most recent affiliation. |
| Homepage | http://tnoncology.com/ |
| OpenAlex ID | https://openalex.org/I4210135086 |
| Region | Tennessee |
| Researchers | 539 |
| ROR ID | https://ror.org/03754ky26 |
| Type | healthcare |
| Works | 3,841 |

## University papers

- [Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation](https://scholariq.org/papers/indications-for-autologous-and-allogeneic-hematopoietic-cell-transplantation/)
- [Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma](https://scholariq.org/papers/rituximab-plus-lenalidomide-in-advanced-untreated-follicular-lymphoma/)
- [Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study](https://scholariq.org/papers/safety-and-activity-of-the-anti-cd79b-antibody-drug-conjugate-polatuzumab/)
- [Secondary solid cancer screening following hematopoietic cell transplantation](https://scholariq.org/papers/secondary-solid-cancer-screening-following-hematopoietic-cell-transplantation/)
- [Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms](https://scholariq.org/papers/phase-i-first-in-human-dose-escalation-study-of-the-oral-sf3b1-modulator-h3b/)
- [Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy](https://scholariq.org/papers/standardizing-definitions-of-hematopoietic-recovery-graft-rejection-graft/)
- [Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee](https://scholariq.org/papers/personalizing-busulfan-based-conditioning-considerations-from-the-american/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.